Search

Your search keyword '"Ángel Ponferrada-Díaz"' showing total 9 results
Start Over Author "Ángel Ponferrada-Díaz"
9 results on '"Ángel Ponferrada-Díaz"'

1. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

Author

Celia Gómez-Labrador, Elena Ricart, Marisa Iborra, Eva Iglesias, María Dolores Martín-Arranz, Luisa de Castro, Ruth De Francisco, Francisco Javier García-Alonso, Ana Sanahuja, Carla J. Gargallo-Puyuelo, Francisco Mesonero, María José Casanova, Míriam Mañosa, Montserrat Rivero, Marta Calvo, Mónica Sierra-Ausin, Carlos González-Muñoza, Xavier Calvet, Santiago García-López, Jordi Guardiola, Lara Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez, Yamile Zabana, Mercè Navarro-Llavat, Rufo Lorente Poyatos, Marta Piqueras, Leyanira Torrealba, Fernando Bermejo, Ángel Ponferrada-Díaz, José L. Pérez-Calle, Manuel Barreiro-de Acosta, Coral Tejido, José Luis Cabriada, Ignacio Marín-Jiménez, Óscar Roncero, Yolanda Ber, Luis Fernández-Salazar, Blau Camps Aler, Alfredo J. Lucendo, Jordina Llaó, Luis Bujanda, Carmen Muñoz Villafranca, Eugeni Domènech, María Chaparro, and Javier P. Gisbert

Subjects
biologics, biosimilars, targeted therapy, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, Pharmacy and materia medica, RS1-441
Abstract

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn’s disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.

Published
2024
Full Text
View/download PDF

3. Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

Author

Teresa, Valdés Delgado, primary, Rául, Olmedo Martín, additional, Marisa, Iborra, additional, Claudia, Herrera de Guisé, additional, Esteban, Fuentes-Valenzuela, additional, Luigi, Melcarne, additional, Mª Mar, Martín-Rodríguez, additional, Lilyan, Kolle Casso, additional, Luisa, De Castro Parga, additional, Ángel, Ponferrada Díaz, additional, Raquel, Vicente Lidón, additional, Noemí, Manceñido Marcos, additional, Benito, Velayos Jiménez, additional, Marta, Lázaro Sáez, additional, Beatriz, López Cauce, additional, Francisco, Mesonero Gismero, additional, Pau, Gilabert Álvarez, additional, and Federico, Argüelles-Arias, additional

Published
2023
Full Text
View/download PDF

4. sj-docx-3-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

Author

Teresa, Valdés Delgado, Rául, Olmedo Martín, Marisa, Iborra, Claudia, Herrera de Guisé, Esteban, Fuentes-Valenzuela, Luigi, Melcarne, Mª Mar, Martín-Rodríguez, Lilyan, Kolle Casso, Luisa, De Castro Parga, Ángel, Ponferrada Díaz, Raquel, Vicente Lidón, Noemí, Manceñido Marcos, Benito, Velayos Jiménez, Marta, Lázaro Sáez, Beatriz, López Cauce, Francisco, Mesonero Gismero, Pau, Gilabert Álvarez, and Federico, Argüelles-Arias

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tag-10.1177_17562848231153560 for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study by Valdés Delgado Teresa, Olmedo Martín Rául, Iborra Marisa, Herrera de Guisé Claudia, Fuentes-Valenzuela Esteban, Melcarne Luigi, Martín-Rodríguez Mª Mar, Kolle Casso Lilyan, De Castro Parga Luisa, Ponferrada Díaz Ángel, Vicente Lidón Raquel, Manceñido Marcos Noemí, Velayos Jiménez Benito, Lázaro Sáez Marta, López Cauce Beatriz, Mesonero Gismero Francisco, Gilabert Álvarez Pau and Argüelles-Arias Federico in Therapeutic Advances in Gastroenterology

Published
2023
Full Text
View/download PDF

5. sj-docx-2-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

Author

Teresa, Valdés Delgado, Rául, Olmedo Martín, Marisa, Iborra, Claudia, Herrera de Guisé, Esteban, Fuentes-Valenzuela, Luigi, Melcarne, Mª Mar, Martín-Rodríguez, Lilyan, Kolle Casso, Luisa, De Castro Parga, Ángel, Ponferrada Díaz, Raquel, Vicente Lidón, Noemí, Manceñido Marcos, Benito, Velayos Jiménez, Marta, Lázaro Sáez, Beatriz, López Cauce, Francisco, Mesonero Gismero, Pau, Gilabert Álvarez, and Federico, Argüelles-Arias

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tag-10.1177_17562848231153560 for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study by Valdés Delgado Teresa, Olmedo Martín Rául, Iborra Marisa, Herrera de Guisé Claudia, Fuentes-Valenzuela Esteban, Melcarne Luigi, Martín-Rodríguez Mª Mar, Kolle Casso Lilyan, De Castro Parga Luisa, Ponferrada Díaz Ángel, Vicente Lidón Raquel, Manceñido Marcos Noemí, Velayos Jiménez Benito, Lázaro Sáez Marta, López Cauce Beatriz, Mesonero Gismero Francisco, Gilabert Álvarez Pau and Argüelles-Arias Federico in Therapeutic Advances in Gastroenterology

Published
2023
Full Text
View/download PDF

6. 36 - EFECTIVIDAD Y SEGURIDAD DE LA TERAPIA CON USTEKINUMAB Y VEDOLIZUMAB EN PACIENTES CON FÍSTULA PERIANAL COMPLEJA: ESTUDIO HEAL

Author

María José Casanova, María Chaparro, Berta Caballol, María José García, Francisco Mesonero, Cristina Rubín de Célix, Patricia Suárez-álvarez, Rocío Ferreiro-Iglesias, María del Mar Martín-Rodríguez, Ruth de Francisco, Pilar Varela-Trastoy, Guillermo Bastida, Marta Carrillo-Palau, Andrea Núñez-Ortiz, Patricia Ramírez-de la Piscina, Daniel Ceballos, Daniel Hervías-Cruz, Roser Muñoz-Pérez, Benito Velayos, Fernando Bermejo, David Busquets, Manuel Cabacino, Patricia Camo-Monteverde, Ignacio Marín-Jiménez, Carmen Muñoz, Luisa Carmen de la Peña-Negro, Eva Sierra-Moros, Jesús Barrio, Eduard Brunet-Mas, Luis Bujanda, Fiorella Cañete, Fernando Gomollón, Noemí Manceñido-Marcos, Iago Rodríguez-Lago, María Carmen Rodríguez-Grau, Beatriz Sicilia, Sandra Torra-Alsina, Laura Arranz-Hernández, Daniel Carpio, Mariana Fe García-Sepulcre, Carlos González-Muñoza, José María Huguet, Lucía Márquez-Mosquera, María Pilar López-Serrano, Ángel Ponferrada-Díaz, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023

7. 34 - POSICIONAMIENTO DE LAS TERAPIAS DIRIGIDAS EN LA ENFERMEDAD INFLAMATORIA INTESTINAL (EII) EN VIDA REAL: ESTUDIO TRENDY DEL REGISTRO ENEIDA

Author

Celia Gómez-Labrador, Elena Ricart, Marisa Iborra, Eva Iglesias, M. Dolores Martín-Arranz, Luisa de Castro, Ruth de Francisco, Francisco Javier García-Alonso, Ana Sanahuja Martínez, Carla J. Gargallo-Puyuelo, Francisco Mesonero, María José Casanova, Miriam Mañosa, Montserrat Rivero, Marta Calvo, Mónica Sierra-Ausin, Carlos González-Muñoza, Xavier Calvet, Santiago García-López, Jordi Guardiola, Lara Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez, Yamile Zabana, Merce Navarro, Rufo Lorente Poyatos, Marta Piqueras, Leyanira Torrealba, Fernando Bermejo, Ángel Ponferrada Díaz, José L Pérez-Calle, Manuel Barreiro-de Acosta, Coral Tejido, José Luis Cabriada, Ignacio Marín-Jiménez, Óscar Roncero, Yolanda Ber, Luis Fernández-Salazar, Blau Camps Aler, Alfredo J Lucendo Villarín, Jordina Llaó, Luis Bujanda, Carmen Muñoz Villafranca, Eugeni Domènech, María Chaparro, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023

8. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

Author

Yamile, Zabana, Ignacio, Marín-Jiménez, Iago, Rodríguez-Lago, Isabel, Vera, María Dolores, Martín-Arranz, Iván, Guerra, Javier, P Gisbert, Francisco, Mesonero, Olga, Benítez, Carlos, Taxonera, Ángel, Ponferrada-Díaz, Marta, Piqueras, Alfredo, J Lucendo, Berta, Caballol, Míriam, Mañosa, Pilar, Martínez-Montiel, Maia, Bosca-Watts, Jordi, Gordillo, Luis, Bujanda, Noemí, Manceñido, Teresa, Martínez-Pérez, Alicia, López, Cristina, Rodríguez-Gutiérrez, Santiago, García-López, Pablo, Vega, Montserrat, Rivero, Luigi, Melcarne, María, Calvo, Marisa, Iborra, Manuel, Barreiro de Acosta, Beatriz, Sicilia, Jesús, Barrio, José Lázaro, Pérez Calle, David, Busquets, Isabel, Pérez-Martínez, Mercè, Navarro-Llavat, Vicent, Hernández, Federico, Argüelles-Arias, Fernando, Ramírez Esteso, Susana, Meijide, Laura, Ramos, Fernando, Gomollón, Fernando, Muñoz, Gerard, Suris, Jone, Ortiz de Zarate, José María, Huguet, Jordina, Llaó, Mariana Fe, García-Sepulcre, Mónica, Sierra, Miguel, Durà, Sandra, Estrecha, Ana, Fuentes Coronel, Esther, Hinojosa, Lorenzo, Olivan, Eva, Iglesias, Ana, Gutiérrez, Pilar, Varela, Núria, Rull, Pau, Gilabert, Alejandro, Hernández-Camba, Alicia, Brotons, Daniel, Ginard, Eva, Sesé, Daniel, Carpio, Montserrat, Aceituno, José Luis, Cabriada, Yago, González-Lama, Laura, Jiménez, María, Chaparro, Antonio, López-San Román, Cristina, Alba, Rocío, Plaza-Santos, Raquel, Mena, Sonsoles, Tamarit-Sebastián, Elena, Ricart, Margalida, Calafat, Sonsoles, Olivares, Pablo, Navarro, Federico, Bertoletti, Horacio, Alonso-Galán, Ramón, Pajares, Pablo, Olcina, Pamela, Manzano, Eugeni, Domènech, Maria, Esteve, On Behalf Of The Eneida Registry Of Geteccu, Universidad de Sevilla. Departamento de Medicina, Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, and Consorci Sanitari de Terrassa

Subjects
COVID-19, SARS-CoV-2, inflammatory bowel disease, 5-aminosalicylates, immunosuppression, Immunosupressió, Factors de risc en les malalties, Risk factors in diseases, terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunosupresión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Inflammatory bowel diseases, COVID-19 (Malaltia), enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Inflammatory bowel disease, Malalties inflamatòries intestinals, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació, Immunosuppression
Abstract

COVID-19; Immunosuppression; Inflammatory bowel disease COVID-19; Immunosupressió; Malaltia inflamatòria intestinal COVID-19; Inmunosupresión; Enfermedad inflamatoria intestinal (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3−5.9), occupational risk (OR: 2.9; 95%CI: 1.8−4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2−2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09−0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results